Are Diclofenac (NSAID) and Serratiopeptidase approved for use in a 13-year-old pediatric patient?

Diclofenac and Serratiopeptidase Approval Status in a 13-Year-Old

Diclofenac is NOT FDA-approved for pediatric use, but can be used off-label at the treating physician's discretion based on clinical experience, while serratiopeptidase lacks sufficient evidence to support its use in any age group and should be avoided. 1, 2, 3

Diclofenac Regulatory Status and Clinical Use

FDA Approval Status

• The FDA drug label explicitly states: "Safety and effectiveness in pediatric patients have not been established" 2
• Despite lack of formal approval, the Pan-American League of Associations for Rheumatology (PANLAR) 2025 guidelines acknowledge that diclofenac can be considered at the treating physician's discretion based on clinical experience in children with polyarticular juvenile idiopathic arthritis (JIA) 1

Evidence for Efficacy in Adolescents

• Diclofenac demonstrates effective analgesia for perioperative acute pain in children, with a number needed to treat (NNT) of 3.6 for reducing rescue analgesia compared to placebo 4
• Compared with non-NSAID analgesics, diclofenac reduces nausea/vomiting with an NNT of 7.7 4
• The drug is 100% absorbed orally with peak plasma levels at approximately 1 hour, though only 50% reaches systemic circulation due to first-pass metabolism 2

Pharmacokinetic Considerations for 13-Year-Olds

• Adolescents aged 13 years and older of average weight can be dosed similarly to adults, with appropriate weight-based adjustments 5
• In children generally, the volume of distribution and clearance of diclofenac are increased compared to adults, potentially requiring higher loading/maintenance doses 6
• The elimination half-life remains similar to adults at approximately 2 hours 2

Safety Profile in Pediatric Populations

• Serious adverse reactions occur in fewer than 0.24% of children treated with diclofenac for acute pain 4
• The types of serious adverse reactions are similar to those in adults, including renal, gastrointestinal, hematological, and immunologic effects 7
• No increase in bleeding requiring surgical intervention has been documented in perioperative use 4
• Diclofenac is more than 99% bound to serum proteins and is substantially excreted by the kidney, requiring caution in patients with renal impairment 2

Preferred Alternatives with Pediatric Approval

• Naproxen is the preferred first-choice NSAID in children due to its evidence-supported efficacy and safety profile 1
• If naproxen is contraindicated or unavailable, FDA/EMA-approved alternatives include: ibuprofen, indomethacin, meloxicam, tolmetin, etodolac, ketorolac, oxaprozin, and celecoxib 1
• For adolescents, naproxen can be dosed at 5-7.5 mg/kg every 12 hours based on body weight 1

Critical Pitfalls to Avoid

• Do not use diclofenac as first-line therapy when evidence-based alternatives like naproxen or ibuprofen are available 1
• Avoid acetylsalicylic acid (aspirin) in children with JIA despite FDA/EMA approval due to controversial efficacy, safety concerns, and toxicity risks 1
• Treatment should be initiated with the lowest age-appropriate or weight-based dose, kept as short as possible for non-chronic conditions, and regularly monitored for adverse effects 7

Serratiopeptidase Evidence and Recommendations

Lack of Scientific Evidence

• The existing scientific evidence for serratiopeptidase is insufficient to support its use as an analgesic or health supplement in any population, including pediatrics 3
• A systematic review of 24 clinical studies found that evidence supporting serratiopeptidase as an anti-inflammatory and analgesic agent is based on clinical studies with poor methodology 3
• Only a few randomized controlled trials exist, typically placebo-controlled with small sample sizes, unspecified dosing/duration, and unclear outcome definitions 3

Safety Data Deficiency

• Data on the safety and tolerability of serratiopeptidase is lacking, with no long-term safety data available 3
• There are no pediatric-specific studies evaluating serratiopeptidase efficacy or safety 3

Clinical Recommendation

• Serratiopeptidase should not be used in a 13-year-old patient due to insufficient evidence of efficacy and lack of safety data 3
• Evidence-based recommendations on the analgesic, anti-atherosclerotic efficacy, safety, and tolerability of serratiopeptidase are needed before clinical use can be justified 3

Practical Algorithm for NSAID Selection in a 13-Year-Old

1. First-line: Naproxen 5-7.5 mg/kg every 12 hours (FDA-approved, best pediatric evidence) 1

2. Second-line alternatives if naproxen contraindicated: Ibuprofen, meloxicam, or other FDA-approved pediatric NSAIDs 1

3. Consider diclofenac only if: All approved alternatives are contraindicated or ineffective, with informed consent regarding off-label use and close monitoring for adverse effects 1, 4

4. Avoid entirely: Serratiopeptidase (insufficient evidence) and aspirin (toxicity concerns in JIA) 1, 3